Postpartum Hemorrhage Clinical Trial
Official title:
Kenya: An Implementation Study on the Barriers and Facilitators of Scaling up the Innovative, Low-cost Ellavi Uterine Balloon Tamponade for Postpartum Hemorrhage
Verified date | April 2022 |
Source | PATH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this implementation research study is to generate evidence that informs the successful uptake and adoption of the Ellavi Uterine Balloon Tamponade (UBT) within Kenyan postpartum hemorrhage (PPH) management programs. The investigators aim to improve the likelihood that the Ellavi UBT will be integrated into the Kenyan health care system by obtaining critical feedback from stakeholders and health care providers on the barriers and facilitators towards its successful adoption and roll out. The research will be done in three purposively selected University of Nairobi affiliated hospitals in Nairobi county, Kenya. This study will therefore be exploratory and use a non-experimental design. The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. The investigators will then gather feedback from the obstetric healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)). This process will help to generate training and facility level recommendations for improved uptake and integration into the local maternal care package. Case report forms and semi-quantitative surveys will be completed by obstetrical care providers to evaluate the primary outcomes of acceptability and feasibility by measuring: context of use, accuracy of use, perceptions of the device, user confidence, acceptability, usability, facilitators of use, barriers to use, use-patterns, and insights into training effectiveness. The secondary outcomes will include financial data to determine the cost of introducing the Ellavi UBT into the Kenyan PPH management protocols and the health system. The study will not involve the storage of biological samples. There is not a direct benefit of the study to the individual participants. All study participants will sign consent forms.
Status | Completed |
Enrollment | 200 |
Est. completion date | December 30, 2021 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - Obstetricians, medical officers, clinical officers, and midwives who recently participated in a PPH/Ellavi UBT training or managed a refractory PPH case (with or without the use of an Ellavi UBT (within the past 72 hours) at one of the 3 participating health care facilities. - Hospital administrators, supply store managers and/or procurement staff Exclusion Criteria: - Obstetricians, medical officers, clinical officers, and midwives working at the facility who do not agree or consent to participate. |
Country | Name | City | State |
---|---|---|---|
Kenya | Kenyatta National Hospital | Nairobi |
Lead Sponsor | Collaborator |
---|---|
PATH | Department for International Development, United Kingdom, University of Nairobi |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the appropriateness, acceptability and feasibility of using the Ellavi UBT via semi-quantitative surveys (quantitative and qualitative measures) with health care providers in Nairobi County. | Determine feasibility by measuring: 1) user comprehension of the Ellavi UBT usage steps and accuracy of use by evaluating assembly, timing of use, relevance for patient's health status (semi-quantitative measures), 2) facilitators of use and barriers to use (open ended, qualitative questions on facility placement, leadership influence, procurement channels, patient feedback), and 3) insights into training effectiveness (opened ended qualitative questions on preferred methods of training, quality of teaching provided). These outcome measures will be evaluated using both quantitative (multiple choice, likert scale) and qualitative (open ended explanations) responses.
Determine acceptability by measuring: perceptions of the device (likert scale), attitudes towards the device (likert scale), user confidence (likert scale), and usability (likert scale). Determine appropriateness by measuring: patterns of use with open ended qualitative questions. |
6 months | |
Primary | Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT by examining hospital record books and collecting quantitative data. | Determine the adoption, penetration, sustainability and fidelity of implementing the Ellavi UBT device into PPH care at 3 health care facilities using semi-quantitative surveys and hospital level record books.
Determine penetration: # facilities participating, # health workers trained, % of all health workers trained at each site. Determine adoption: % of facilities that adopted UBT devices, # of trained health workers who used the UBT. Determine sustainability: proportion of facilities and health worker who use UBTs/month, for 6 months; %l of providers that use the UBT correctly for >80% of cases. Determine fidelity: % of all health workers surveyed that used the Ellavi UBT. |
6 months | |
Secondary | Determine the cost of introducing the Ellavi UBT into the PPH management protocol and health system by examining cost data, hospital procurement records, and quantifying labor hours worked. | Determine the costs of the different training course components by reviewing charges incurred.
Determine the costs for country-level activities associated with UBT introduction into the PPH management protocols. This includes costs for meetings, advocacy, and communication materials (e.g. review spreadsheets of costs incurred). Determine the frequency and duration of stock outs of: condoms, catheters, IV fluids (sterilized materials), and sutures by surveying hospital inventory stock. Determine the costs of staff time spent on assembling a condom catheter UBT. Determine the costs of supplied pieces to assemble condoms catheters. |
6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 |